{"id":17951,"date":"2023-06-13T23:14:00","date_gmt":"2023-06-13T15:14:00","guid":{"rendered":"https:\/\/flcube.com\/?p=17951"},"modified":"2024-12-14T23:16:57","modified_gmt":"2024-12-14T15:16:57","slug":"mass-general-brigham-partners-with-simcere-pharmaceutical-for-cancer-and-autoimmune-disease-research","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=17951","title":{"rendered":"Mass General Brigham Partners with Simcere Pharmaceutical for Cancer and Autoimmune Disease Research"},"content":{"rendered":"\n

Top-tier US medical institution Mass General Brigham Incorporated (MGB) has signed a sponsored research agreement with Chinese firm Simcere Pharmaceutical Group (HKG: 2096<\/a>). The collaboration will see up to eight research groups at MGB receive funding for select projects over a two-year period, with a focus on developing new treatment options for patients with cancer, autoimmune, and central nervous system (CNS) diseases.<\/p>\n\n\n\n

Expanding Research and US Presence<\/strong>
This agreement marks a significant step in Simcere’s expansion of its US footprint. The company already operates the Boston Innovation Center (BIC) in Cambridge, Massachusetts. In a separate announcement, Simcere revealed that its cancer-focused subsidiary, Zaiming, will establish a new unit, Simcere Zaiming Inc., also based in Massachusetts. This move is expected to bolster Simcere’s research and development capabilities in the US, particularly in the areas of cancer, autoimmune, and CNS diseases.<\/p>\n\n\n\n

Implications of the Research Agreement<\/strong>
The research agreement with MGB underscores Simcere’s commitment to advancing medical research and expanding its global reach. By collaborating with a prestigious institution like Mass General Brigham, Simcere aims to accelerate the discovery and development of innovative therapies for serious diseases. This partnership has the potential to enhance patient outcomes and contribute to the global medical community’s understanding and treatment of cancer, autoimmune, and CNS diseases.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Top-tier US medical institution Mass General Brigham Incorporated (MGB) has signed a sponsored research agreement…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,6],"tags":[65,16,1099,271],"class_list":["post-17951","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","category-rd","tag-auto-immune","tag-cancer","tag-hkg-2096","tag-simcere-pharmaceutical"],"yoast_head":"\nMass General Brigham Partners with Simcere Pharmaceutical for Cancer and Autoimmune Disease Research - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Top-tier US medical institution Mass General Brigham Incorporated (MGB) has signed a sponsored research agreement with Chinese firm Simcere Pharmaceutical Group (HKG: 2096). The collaboration will see up to eight research groups at MGB receive funding for select projects over a two-year period, with a focus on developing new treatment options for patients with cancer, autoimmune, and central nervous system (CNS) diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=17951\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mass General Brigham Partners with Simcere Pharmaceutical for Cancer and Autoimmune Disease Research\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=17951\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-13T15:14:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-14T15:16:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17951#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17951\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mass General Brigham Partners with Simcere Pharmaceutical for Cancer and Autoimmune Disease Research\",\"datePublished\":\"2023-06-13T15:14:00+00:00\",\"dateModified\":\"2024-12-14T15:16:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17951\"},\"wordCount\":230,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Cancer\",\"HKG: 2096\",\"Simcere Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\",\"R&D\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=17951#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17951\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=17951\",\"name\":\"Mass General Brigham Partners with Simcere Pharmaceutical for Cancer and Autoimmune Disease Research - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-06-13T15:14:00+00:00\",\"dateModified\":\"2024-12-14T15:16:57+00:00\",\"description\":\"Top-tier US medical institution Mass General Brigham Incorporated (MGB) has signed a sponsored research agreement with Chinese firm Simcere Pharmaceutical Group (HKG: 2096). The collaboration will see up to eight research groups at MGB receive funding for select projects over a two-year period, with a focus on developing new treatment options for patients with cancer, autoimmune, and central nervous system (CNS) diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17951#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=17951\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17951#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mass General Brigham Partners with Simcere Pharmaceutical for Cancer and Autoimmune Disease Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mass General Brigham Partners with Simcere Pharmaceutical for Cancer and Autoimmune Disease Research - Insight, China's Pharmaceutical Industry","description":"Top-tier US medical institution Mass General Brigham Incorporated (MGB) has signed a sponsored research agreement with Chinese firm Simcere Pharmaceutical Group (HKG: 2096). The collaboration will see up to eight research groups at MGB receive funding for select projects over a two-year period, with a focus on developing new treatment options for patients with cancer, autoimmune, and central nervous system (CNS) diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=17951","og_locale":"en_US","og_type":"article","og_title":"Mass General Brigham Partners with Simcere Pharmaceutical for Cancer and Autoimmune Disease Research","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=17951","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-06-13T15:14:00+00:00","article_modified_time":"2024-12-14T15:16:57+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=17951#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=17951"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mass General Brigham Partners with Simcere Pharmaceutical for Cancer and Autoimmune Disease Research","datePublished":"2023-06-13T15:14:00+00:00","dateModified":"2024-12-14T15:16:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=17951"},"wordCount":230,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Cancer","HKG: 2096","Simcere Pharmaceutical"],"articleSection":["Company","Deals","R&D"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=17951#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=17951","url":"https:\/\/flcube.com\/?p=17951","name":"Mass General Brigham Partners with Simcere Pharmaceutical for Cancer and Autoimmune Disease Research - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-06-13T15:14:00+00:00","dateModified":"2024-12-14T15:16:57+00:00","description":"Top-tier US medical institution Mass General Brigham Incorporated (MGB) has signed a sponsored research agreement with Chinese firm Simcere Pharmaceutical Group (HKG: 2096). The collaboration will see up to eight research groups at MGB receive funding for select projects over a two-year period, with a focus on developing new treatment options for patients with cancer, autoimmune, and central nervous system (CNS) diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=17951#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=17951"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=17951#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mass General Brigham Partners with Simcere Pharmaceutical for Cancer and Autoimmune Disease Research"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17951"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17951\/revisions"}],"predecessor-version":[{"id":17952,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17951\/revisions\/17952"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17951"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17951"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}